Accès ouvert
2026
preprint
OpenAlex
Piergiorgio Grillo, Chan Wang, Antonio Pisani, 강운 et autres
Abstract The heterogenous clinical and pathophysiological presentation of idiopathic Parkinson’s Disease (iPD) suggests the existence of underlying distinct biological subtypes. A better definition of PD subtypes is crucial for the development of target disease modifier approaches. Using data from the Parkinson’s Precision …
us, it, ca, se
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Alessandra Calculli, Deborah Di Martino, Piergiorgio Grillo, Gabriele Bellini et autres
Background Isolated REM sleep behavior disorder (iRBD) is a prodromal stage of α-synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Evaluating trajectories of phenoconversion is crucial in this population. Plasma neurofilament light chain (NfL), a …
it, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Lorenzo Gaetani, Luisa Agnello, Andrea Pilotto, Alberto Benussi et autres
BACKGROUND: Blood-based biomarkers are reshaping the diagnostic paradigm of Alzheimer’s disease (AD), offering a minimally invasive alternative to cerebrospinal fluid (CSF) and positron emission tomography (PET). However, their clinical implementation requires harmonized analytical validation, standardized procedures, and clear guidance on appropriate use …
us, it, se
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Piergiorgio Grillo, Giulietta Maria Riboldi, Antonio Pisani, Un Jung Kang et autres
BackgroundData-driven approaches identified Mild Motor Predominant (MMP), Intermediate (IM), and Diffuse Malignant (DM) as Parkinson's Disease (PD) subtypes with different motor and non-motor impairment at diagnosis. It remains unclear whether these subtypes remain stable over time or whether they represent distinct biological …
it, us, ca, se
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David‐Erick Lafontant et autres
BACKGROUND: The cerebrospinal fluid alpha-synuclein seed amplification assay (CSFasynSAA) detects alpha-synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined. OBJECTIVES: Describe clinical and neuroimaging characteristics of CSFasynSAA-negative sPD individuals …
us, it, gb, ca, se, de, il
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Piergiorgio Grillo, Daniela Maftei, Alessandra Calculli, Tommaso Schirinzi et autres
STUDY OBJECTIVES: PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in Parkinson's disease (PD), but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its …
it, us
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Piergiorgio Grillo, Daniela Maftei, Alessandra Calculli, Tommaso Schirinzi et autres
ABSTRACT Objectives PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in PD, but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its receptors (PKR1 …
it
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David-Erick Lafontant et autres
Abstract Background The CSF alpha-synuclein seed amplification assay (CSFasynSAA) detects alpha-synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined. Objectives Describe clinical and neuroimaging characteristics of CSFasynSAA negative sPD …
us, it, gb, ca, se, de, il, au
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Giulia Di Lazzaro, Federico Paolini Paoletti, Giovanni Bellomo, Tommaso Schirinzi et autres
BACKGROUND: Parkinson's disease (PD) has different progression rates and disease characteristics according to age of onset, the younger being less cognitively affected and experiencing more motor fluctuations. We explored different pathophysiologic mechanisms underlying PD in patients of different ages independently from disease …
it
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Piergiorgio Grillo, Deborah Di Martino, Alessandra Calculli, Roberto De Icco et autres
Physical exercise (PE) improves clinical outcomes in individuals with Parkinson's disease (PD) through unclear mechanisms. Irisin, a neuroprotective protein released by myocytes during PE, may play a role, but in vivo data in PD are limited. We investigated plasma irisin in a …
it, us
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Piergiorgio Grillo, Giulietta Maria Riboldi, Antonio Pisani, Un Jung Kang et autres
Abstract Background Data-driven approaches identified Mild Motor Predominant (MMP), Intermediate (IM), and Diffuse Malignant (DM) as Parkinson’s Disease (PD) subtypes with different motor and non-motor impairment at diagnosis. It remains unclear whether these subtypes remain stable over time or whether they represent …
it, us, ca, se
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jacopo Bissacco, Roberta Bovenzi, Matteo Conti, Clara Simonetta et autres
BACKGROUND: Gastrointestinal dysfunction (GID) accompanies any phase of Parkinson's disease (PD), underlying differential clinical-pathological trajectories. OBJECTIVE: To investigate associations between GID and peripheral immune or neurodegeneration-related markers in PD. METHODS: One-hundred-and-fourteen patients (n = 55 de novo, DN; n = 59 middle-advanced, …
it, gb
(code pays fourni par la source)